

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1(Currently amended). An expression vector for the production of ~~[[an]]~~ a mixture of icIL-1ra-II protein proteins beginning at amino acid residue position +1 and +2 from the deduced start of translation on the icIL-1ra-II coding sequence, comprising a genomic DNA sequence encoding a human growth hormone signal peptide ~~genomic DNA sequence~~, joined to a DNA segment encoding intracellular IL-1 receptor antagonist type II (icIL-1ra-II) and operably linked to a promoter sequence, whereby said icIL-1ra-II ~~[[is]]~~ proteins are expressed from said promoter sequence to produce ~~[[an]]~~ a mixture of icIL-1ra-II proteins with the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:11 at the N-terminus.

Claim 2 (Cancelled).

3(Previously presented). An isolated host cell line transformed with the expression vector of claim 1.

Claim 4 (Cancelled).

5 (Previously presented). An isolated host cell line in accordance with claim 3, wherein said cell is an endogenous cell of a human host.

Claim 6 (Cancelled).

7 (Previously presented). A method for producing a recombinant icIL-1ra-II comprising the steps of:

culturing a host cell line according to claim 3 to express and produce a recombinant glycosylated icIL-1ra-II;

recovering the produced recombinant glycosylated icIL-1ra-II.

Claim 8 (Cancelled).

9 (Currently amended). An isolated glycosylated icIL-1ra-II beginning at amino acid residue position +2 from the deduced start of translation on the icIL-1ra-II coding sequence and having the amino acid sequence of SEQ ID NO:11 at the N-terminus.

10 (Currently amended). The glycosylated icIL-1ra-II according to claim 9 having an apparent molecular weight of about 27 kDa on SDS-PAGE under reducing conditions with 15% acrylamide.

11 (Currently amended). The glycosylated icIL-1ra-II according to claim 9 having an apparent molecular weight of about 30 kDa on SDS-PAGE under reducing conditions with 15% acrylamide.

12 (Currently amended). A pharmaceutical composition, comprising the glycosylated icIL-1ra-II according to claim 9 in a therapeutically effective amount and a pharmaceutically acceptable excipient.

13 (Withdrawn). A method for reducing the amount of IL-1 in a patient having a condition associated with overexpression of IL-1, comprising administering the pharmaceutical composition according to claim 12 to a patient in need thereof.

14 (Withdrawn). A method for reducing the amount of IL-1 at a desired site in a human patient, comprising introducing a vector in accordance with claim 3 into appropriate endogenous human cells at the desired site to produce transformed cells which will express icIL-1ra-II at the desired site.

Claim 15-18 (Cancelled).